[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"photodamaged-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:photodamaged-skin":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100646746","phase-2-study-comparing-two-serums-with-intense-pulsed-light-for-the-treatment-of-moderate-to-severe-photodamage-and-crepiness-on-the-forearms-100646746",false,"NCT07686198","Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms","A Randomized, Double-Blind, Vehicle-Controlled, Split-Arm Study of Twice Daily Re-Q Pro-Longevity Serum in Combination With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms","Inclusion Criteria:\n\n1. Female participants aged 50 to 80 years.\n2. Fitzpatrick skin types I-IV.\n3. Moderate to severe photodamage and crepiness on the arms, based on clinical evaluation, including fine wrinkling, coarse wrinkling, photodamage, and a global assessment as assessed with the 10-point Dermatologic Assessment Form and Photographic Scale\n4. Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.\n5. Willing to sign an informed consent form and photography release for research, publication, and\u002For commercial use.\n6. In good general health as determined by the investigator based on medical history and clinical judgment.\n7. Willing to maintain the study skincare regimen and refrain from introducing new topical or procedural treatments to the forearms during the study period.\n8. Negative urine pregnancy test at all visits for participants of childbearing potential.\n9. Participants must be of non-childbearing potential, defined as: a. History of hysterectomy or bilateral oophorectomy, or b. No menses for at least 12 consecutive months without an alternative medical cause. Or, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include: i. Oral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) ii. Intrauterine coil iii. Bilateral tubal ligation iv. Hysterectomy v. Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) vi. Abstinence (must agree to use a barrier method if sexual activity begins during the study) vii. Partner with a vasectomy (if not, participant must agree to use a barrier method)\n\nExclusion Criteria:\n\n1. Patients with dark hair in the treatment area who are unwilling to shave the treated area prior to IPL treatments or who are unwilling to proceed knowing IPL will eliminate at least 50% of the hairs in the treatment area\n2. A suntan in the treatment area or use of sunless tanner\u002Fspray-tan in the treatment areas 4 weeks prior to study treatment\n3. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.\n4. Use of at-home energy-based devices intended for rejuvenation or fibroblastic\u002Fcollagen stimulation on the treatment area within 30 days prior to treatment and during the study period.\n5. Use of GLP-1 medications or metformin within 3 months prior to enrollment\n6. Pregnancy, plans to become pregnant during the study period, or current breastfeeding.\n7. History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).\n8. Current or recent use (within the past 3 months) of systemic immunosuppressive medications.\n9. Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.\n10. Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.\n11. Active smoking tobacco or use of nicotine-containing products within 6 months prior to enrollment.\n12. Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.\n13. Unwillingness to refrain from undergoing any additional aesthetic treatments to the arms (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.\n14. History of keloids or scarring\u002Ftattoos in the treatment area",true,"FEMALE","50 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The primary objective is to compare Re-Q Pro-Longevity serum versus vehicle serum combined with Intense Pulsed Laser for the treatment of moderate to severe photodamage and crepiness on the dorsal forearms.",[29],"Photodamaged Skin",[31,32,33,34],"Crepiness","Photodamage","Sun Damage","Arms","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-07","ACTUAL",{"date":41,"type":22},"2026-07-10",{"date":43,"type":22},"2027-01-30",{"name":45,"class":46},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":47},"100645302","a-synergistic-approach-to-remodeling-of-photodamaegd-skin-exploring-laser-assisted-biostimulator-delivery-100645302","NCT07680426","A Synergistic Approach to Remodeling of Photodamaegd Skin: Exploring Laser-Assisted Biostimulator Delivery","A Synergistic Approach to Remodeling of Photodamaegd Skin: Exploring Laser-Assisted Biostimulator Delivery Through AI-Assisted In Vivo Imaging and Transcriptomics","SYNTROMICS","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical signs of photodamage. Signs will include low-grade actinic keratoses (Olsen grade I-II), solar lentigines, telangiectasia, or other visible markers of chronic photodamage.\n\nExclusion Criteria:\n\n* Active skin diseases in the treatment site\n* Laser treatment, PLLA, or other treatments in the treatment area within the past 24 months\n* Pregnancy or breastfeeding\n* Contraindications to AFL or Sculptra","ALL","18 Years",{"count":59,"type":22},33,[61],"NA","Photodamaged skin increases the risk of skin cancer, highlighting the need for preventive treatments. Laser-assisted drug delivery (LADD) using ablative fractional lasers (AFL) enhances topical drug delivery and has proven safe and effective. Integrating non-invasive optical imaging techniques with transcriptomic gene expression profiling enables evaluation of the response of different skin layers to such interventions.\n\nIt is hypothesized that AFL-assisted delivery of biostimulators exerts synergistic regenerative effects on photodamaged skin, resulting in superior clinical, molecular, and morphological improvements, as well as enhanced epidermal and dermal remodeling, compared with either monotherapy alone. The study aims to provide an in-depth understanding of the individual and combined effects of AFL and biostimulators on the regeneration of photodamaged skin through clinical assessments, non-invasive imaging, and transcriptomic analysis.",[29,64],"Skin Cancer Prevention",[66,67,68,69,70,71,72,73,74,75],"laser-assisted drug delivery","optical coherence tomography","poly-l-lactic acid","transcriptomics","ablative fractional laser","Photodamaged skin","skin cancer prevention","sculptra","skin diseases","non-invasive imaging","2026-06-25",{"date":78,"type":39},"2026-07-02",{"date":80,"type":22},"2026-09-01",{"date":82,"type":22},"2027-12",{"name":84,"class":46},"Bispebjerg Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":19,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100610039","2910-nm-erbium-doped-fluoride-fiber-glass-laser-for-the-treatment-of-advanced-perioral-lines-and-wrinkles-100610039","NCT07222397","2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles","Evaluation of the 2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles","Inclusion Criteria:\n\n1. Fitzpatrick skin type I-IV.\n2. Male or female.\n3. Subjects must be between 50 and 80 years of age.\n4. Subjects must have the ability to receive up to two full face resurfacing laser treatment with specific focus on advanced perioral lines and wrinkles.\n5. Subjects must read, understand, and sign the Informed Consent Form.\n6. Subjects must be willing and able to comply with all follow-up visit requirements.\n7. Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator.\n8. Subjects must be rated as Class II or Class III based on the Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS).\n9. Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion.\n10. Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study.\n\nExclusion Criteria:\n\n1. Subjects must not have active localized or systemic infections.\n2. Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atrophic dermatitis or immunologic abnormalities such as vitiligo.\n3. Subjects must not have had treatments with 5FU, diclofenac, imiquimod, steroids, retinoids, or PDT within 1-month prior to enrollment.\n4. Subjects must not currently be taking Accutane or have taken Accutane within the last 1-month.\n5. Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications.\n6. Subjects must not have had previous surgery and\u002For fat transfer in the treatment area within the last 6-months.\n7. Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area.\n8. Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area.\n9. Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area.\n10. Subjects must not have had neurotoxins within the last 3-months in the treatment area.\n11. Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12 months.\n12. Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling, or energy-based device treatment in the treatment area within the last 3 months.\n13. Subject must not have had an ablative laser treatment in the treatment area within the last 6 months.\n14. Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.\n15. Subject must not have active sunburn or excessively tanned skin.\n16. Subjects must not be pregnant or breastfeeding, think they may be pregnant or are trying to get pregnant during the study.",{"count":21,"type":22},[61],"The primary objective is to assess the efficacy, safety and satisfaction associated with the resurfacing treatment of perioral lines and wrinkles with the 2,910 nm mid-infrared Fiber Laser (UltraClear, Acclaro Medical) using both superficial epidermis ablation capabilities and the deep ablative and coagulative capabilities into the dermis for rejuvenation.\n\nParticipants will receive up to two treatments spaced 6-8 weeks apart, followed by a 1-month and 3-month follow-up visit during which the device will be evaluated for its effectiveness defined as improvement addressing perioral lines and wrinkles utilizing multiple scales completed by the investigator and blinded Independent Photographic Reviewers (IPRs). Additionally, safety, subjective overall aesthetic improvement and satisfaction will be monitored and tracked.",[29,96,97,98],"Rhytids","Lines Skin","Wrinkles and Rhytides","RECRUITING","2025-10-27",{"date":102,"type":39},"2025-10-29",{"date":104,"type":39},"2025-03-01",{"date":106,"type":22},"2026-02",{"name":108,"class":109},"FA Corporation","INDUSTRY"]